AbbVie (NYSE:ABBV - Get Free Report) had its price target lifted by equities researchers at BNP Paribas Exane from $218.00 to $247.00 in a research note issued on Tuesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. BNP Paribas Exane's target price would suggest a potential downside of 1.15% from the stock's previous close.
A number of other analysts also recently commented on the stock. Erste Group Bank upgraded shares of AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. UBS Group boosted their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Monday, July 13th. Morgan Stanley restated an "overweight" rating and issued a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Thursday, April 30th. Finally, Royal Bank Of Canada lifted their price objective on AbbVie from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, July 10th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $274.33.
Get Our Latest Stock Analysis on AbbVie
AbbVie Stock Up 0.8%
Shares of NYSE:ABBV traded up $1.90 during trading on Tuesday, hitting $249.87. 1,581,457 shares of the stock traded hands, compared to its average volume of 6,952,049. The company has a fifty day moving average price of $242.67 and a two-hundred day moving average price of $225.28. AbbVie has a 52-week low of $190.75 and a 52-week high of $267.47. The company has a market cap of $441.47 billion, a price-to-earnings ratio of 70.43, a P/E/G ratio of 0.82 and a beta of 0.30.
AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same quarter in the previous year, the company earned $2.97 earnings per share. The firm's revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie will post 14.07 EPS for the current fiscal year.
Hedge Funds Weigh In On AbbVie
Hedge funds have recently modified their holdings of the business. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $28,000. Imprint Wealth LLC grew its stake in shares of AbbVie by 56.2% during the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Legacy Wealth Managment LLC ID grew its stake in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after purchasing an additional 73 shares in the last quarter. IFC & Insurance Marketing Inc. purchased a new position in AbbVie in the fourth quarter valued at $31,000. Finally, WestEnd Advisors LLC increased its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after buying an additional 85 shares during the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.
More AbbVie News
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: Apogee acquisition strengthens the pipeline: AbbVie is set to acquire Apogee Therapeutics for approximately $10.9 billion, adding zumilokibart, an investigational treatment for atopic dermatitis with planned Phase 3 development. Positive Phase 2 results and potential applications in asthma and eosinophilic esophagitis could help expand AbbVie’s immunology portfolio beyond its existing growth drivers. The transaction is expected to close in the third quarter, subject to approvals. AbbVie to Acquire Apogee for $10.9 Billion
- Positive Sentiment: Botox may gain another indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence. If approved, the fifth use for the brand could broaden its addressable market and support continued growth in aesthetics. AbbVie’s Botox Just Got a Step Closer to a Fifth Use
- Positive Sentiment: Recent operating momentum supports the stock: AbbVie’s latest quarterly results exceeded revenue and earnings expectations, with revenue rising 10.2% year over year. Management cited strong performance from SKYRIZI, RINVOQ and neuroscience products, while brokerages continue to characterize the shares as a “Moderate Buy.” The 5 Most Interesting Analyst Questions From AbbVie’s Q2 Earnings Call
- Neutral Sentiment: Analyst estimate trimmed but rating remains positive: Erste Group Bank lowered its FY2027 EPS forecast to $16.24 from $16.40, but retained a Buy rating. The modest reduction signals limited near-term concern rather than a broad change in the long-term outlook.
- Negative Sentiment: Debt-funded acquisition raises dividend-investor concerns: AbbVie is reportedly taking on approximately $8 billion of debt to help finance the Apogee deal. Although the acquisition could create future growth, added leverage may increase interest costs and constrain financial flexibility, particularly given AbbVie’s already substantial acquisition commitments. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal
About AbbVie
(
Get Free Report)
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
